Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
immune checkpoint inhibitors (ICIs)
immune related adverse events (irAEs)
myocarditis
neurological immune-related adverse events
rechallenge
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
19
03
2024
accepted:
17
06
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation
Identifiants
pubmed: 39040444
doi: 10.3389/fonc.2024.1403658
pmc: PMC11260680
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1403658Informations de copyright
Copyright © 2024 Eldani, Kostine, Faure, Lazaro, Rigothier, Hiriart, Teulières, Poullenot, Haissaguerre, Zysman, Veillon, Vergnenegre, Issa, Domblides, Mary-Prey, Beylot-Barry, Pham-Ledard, Dutriaux, Sole, Duval and Gerard.
Déclaration de conflit d'intérêts
EG: congress fees and investigator for BMS and MSD. RV: speakers’ bureau for BMS. SM-P: consultant on boards for BMS. AP-L: congress fees for BMS. CDu: Clinical investigation in trials, congress fees and member of boards for BMS, MSD. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.